ArticleFrontiers in oncology2025
Molecular and clinical insights into HIV-associated and HIV-negative aggressive B-cell lymphomas: prognostic quantitative biomarker analysis and therapeutic implications.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From CCU to infectious disease ward: HIV-associated high-grade follicular lymphoma presenting with pulmonary thromboembolism and necrotizing pneumonia.AIDS research and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: HIV-associated lymphomas (HALs) exhibit aggressive features and poorer prognosis compared to HIV-negative lymphomas. However, their molecular and clinicopathological characteristics remain unclear in the antiretroviral therapy (ART) era. Methods: We retrospectively analyzed 208 lymphoma patients (57 HALs, 151 HIV-negative lymphomas) diagnosed between July 2019 and March 2024. Quantitative immunohistochemistry evaluated expression levels of Ki67, CD10, BCL6, MUM1, BCL2, and MYC. Independent prognostic factors were identified using multivariate Cox regression analysis, and a survival prediction model was validated by receiver operating characteristic (ROC) curve analysis. Results: HALs exhibited significantly higher proliferative activity (Ki67 AOD: 0.92 vs. 0.82, P < 0.001), more advanced disease stages (Ann Arbor stage III/IV: 77.2% vs. 60.0%, P = 0.022), and increased Epstein-Barr virus (EBV) positivity (51.1% vs. 17.9%, P < 0.001). Immunophenotyping revealed a GCB-like phenotype in HALs, characterized by elevated CD10 and BCL6 expression and decreased MUM1 and BCL2 expression. Patients with HALs had significantly shorter survival (median: 32.1 vs. 46.1 months, P < 0.001). Multivariate analysis identified Ki67 AOD (hazard ratio [HR] = 3.04, 95% confidence interval [CI]: 3.85-10.85), International Prognostic Index (IPI) (HR = 9.35, 95% CI: 4.20-20.82), and ART duration (protective, HR = 0.29/year, 95% CI: 0.19-0.45) as independent prognostic factors. The survival model demonstrated strong predictive accuracy (1-year area under the curve [AUC] = 0.831). Conclusions: HALs exhibit distinct molecular profiles-including elevated EBV infection, a GCB-like phenotype, increased Ki67 AOD, and decreased BCL2 expression-that contribute to significantly poorer survival compared to HIV-negative lymphomas. Integrating Ki67 AOD and IPI scores into prognostic models may enhance individualized prognosis and optimize treatment strategies for HAL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.